No Data
Hang Seng Index's "big change" in December: Pop Mart, Kuaishou expected to be included, will the constituent stocks return to 100?
Currently, the Hang Seng Index in Hong Kong includes 82 stocks, with the ultimate goal of expanding the number of constituent stocks to 100. Analysis suggests that the medical care industry is still the least represented industry in the Hang Seng Index, while consumer staples, discretionary items, real estate, and construction may receive higher weights in the review in the fourth quarter of this year.
Zhitong Hong Kong stocks early knowledge | Hua Hong (01347) received a 40nm MCU order from stmicroelectronics. The hang seng index company today announced the results of the third quarter review.
On November 21st, europe chip giant stmicroelectronics (STM.US) held an investor day event in Paris, France on Wednesday local time, announcing a cooperation with the second largest wafer foundry in china to produce 40nm node microcontrollers (MCUs) in china, in support of its long-term revenue goals.
Hong Kong Stock Exchange Announcement | Baidu Group - SW (09888) net income attributable to Baidu in the third quarter was 7.632 billion yuan, an increase of 14% year-on-year and an increase of 39% month-on-month.
Chinarese Pharma (03320): China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) will sell 51% equity interest in China Resources Shenghuo to Kun Medicine (600422.SH)......
Chinares Pharma (03320.HK): Kunming Pharmaceutical plans to acquire a 51% stake in Chinares Shenghuo.
Gelonghui, November 21 - chinares pharma (03320.HK) announced that the board of directors is pleased to report that on November 21, 2024, china resources sanjiu medical & pharmaceutical and Kun Pharmaceutical signed an equity transfer agreement, whereby china resources sanjiu conditionally agreed to sell and Kun Pharmaceutical conditionally agreed to acquire a 51% stake in chinares pharma Shenghuo, with a total consideration of RMB 1,791 million. It is expected that china resources sanjiu will use the proceeds from the sale of the 51% stake in chinares pharma Shenghuo to supplement its working capital. Following the proposed internal restructuring, it is anticipated that the company's holding in chinares pharma Shenghuo will be diluted from approximately 63.02% to about 39.90%.
Express News | China Resources Pharmaceutical Group Ltd - Cr Sanjiu to Sell 51% Interest in Cr Shenghuo for RMB1,791 Mln
Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.
①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?
No Data
No Data
